FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
23/07/2026
Voltar para busca
Dado oficial do USPTO
ZYTOMICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ZYTOMICS
ST13
US500000079391171Classe
1, 5, 9, 10, 35, 42, 44
Pedido
79391171
Registro
8081487
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
47
Atualização mais recente
23/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 9, 10, 35, 42, 44
Data de depósito
01/11/2023
Data de registro
30/12/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/12/2025
Última transação
23/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
DE
Examinador
BECKER, MARY ELIZABETH
Unidade examinadora
O10
Localização atual
TMO LAW OFFICE 128
Titulares e representantes
Titulares
ZytoVision GmbH
Representantes
Laurence P. Colton SMITH TEMPEL BLAHA LLC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 9Classe 10Classe 35Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals for use in industry and science; chemicals and biochemicals for use in science in the fields of pathologygeneticshuman geneticsmolecular pathologiesmolecular biologymicrobiologybiotechnologylaboratory medicine; chemicals and biochemicals for use in science in the fields of histologycytologyimmunohistologyimmunohistochemistryin situ hybridisationpolymerase chain reaction (PCR)next generation sequencing (NGS)microarray hybridisation in the nature of genetic chip or biochip hybridisationflow cytometry servicesisolation of biomolecules including DNARNA and proteins; nucleic acids in the nature of DNARNAoligonucleotidespolynucleotidesmarked nucleic acids and modified nucleic acidsfor scientific purposes; proteins in the nature of peptide substratesrecombinant proteins and marked proteins for scientific and medical research; antibodies for scientific purposes; DNA probes being biochemical preparations for scientific purposes; RNA probes being biochemical preparations for scientific purposes; oligonucleotide probes being biochemical preparations for scientific purposes; biological tissuehuman stem cellshuman somatic cellshuman cancer cellshuman tissuehuman tissue sectionsfor scientific and medical research; nucleic acidsproteinshuman somatic cellshuman cancer cellsstem cells immobilised on carriers for scientific and medical research
Classe 5
Pharmaceuticals and medical preparations for use in chemotherapy and cancer diagnostics; diagnostic preparations for medical purposes; diagnostic preparations for in-vitro testing for medical use; pharmaceuticalspharmaceutical preparationsmedical products in the nature of diagnostic preparationsmedical preparationschemical products in the nature of chemical reagentschemical preparationsbiochemical products in the nature of chemical reagentsbiochemical preparationsall for use in chemotherapy and cancer diagnostics for medical use; pharmaceuticalmedicalchemical and biochemical preparations for medical purposes in the fields of histologycytologyimmunohistologyimmunohistochemistryin situ hybridisationpolymerase chain reaction (PCR)next generation sequencing (NGS)microarray hybridisation in the nature of genetic chip or biochip hybridisationflow cytometry servicesisolation of biomolecules including DNARNA and proteins; nucleic acids in the nature of DNARNAoligonucleotidespolynucleotidesmarked nucleic acids and modified nucleic acids for medical purposes; proteins in the nature of peptide substratesrecombinant proteins and marked proteins for use in chemotherapy and cancer diagnostics for medical purposes; antibodies for medical purposes; DNA probes being biochemical preparations for chemotherapy and cancer diagnostics for medical use; RNA probes being biochemical preparations for chemotherapy and cancer diagnostics for medical use; oligonucleotide probes being biochemical preparations for chemotherapy and cancer diagnostics for medical use; biological tissuehuman stem cellshuman somatic cellshuman cancer cellshuman tissuehuman tissue sections for use in chemotherapy and cancer diagnostics; nucleic acidsproteinshuman somatic cellshuman cancer cells and human stem cells immobilised on carriers for medical diagnostic purposes
Classe 9
Scientific research and laboratory apparatus in the nature of analysis systemscomprised of automated slide staining instrumentsautomated laboratory instruments for slide assemblystaininglabelingincubationsample preparation instruments in the nature of automated sample processing instrumentsliquid handling robotsnon-medical imaging devices for proteinsnucleic acidshuman cellshuman tissuesrobotic sample handling systems being laboratory robotsmicroscopesspectrophotometersthermal cyclersflow cytometerscomputer hardware with recorded software and downloadable software for conducting and evaluating laboratory procedures for use in the analysis of proteinsnucleic acidshuman cellshuman tissues; educational apparatus and simulators in the nature of medical diagnostic simulators for use as teaching aids for medical procedures; analysis apparatus in the nature of diagnostic apparatus for research laboratory use for conducting and evaluating histologycytologyimmunohistologyimmunohistochemistryin situ hybridisationpolymerase chain reaction (PCR)next generation sequencing (NGS)microarray hybridisation in the nature of genetic chip or biochip hybridisationflow cytometryisolation of biomolecules including DNARNA and proteins; research laboratory analyzers for measuringtesting and analyzing blood and other bodily fluids; analysis apparatus for research laboratories in the nature of diagnostic apparatus for measuringtesting and examining tissuecells and biomolecules including DNARNA and proteins
Classe 10
Medical apparatus and instruments for use in cancer diagnostic and treatment procedures; medical instruments for use in cancer diagnostic and treatment procedures; medical analytical apparatus for analyzing human cells and tissues for the presence of cancerous cells for medical purposes; automatic analyzers for medical diagnosis of cancer in human cells and tissues; physical analyzers for diagnosing cancer for medical use; genetic testing apparatus for medical purposes
Classe 35
Business management consultancy and advisory services; operation of a business for othersholding company services performed for third parties in the nature of business management and business administration of subsidiariesbusiness management of medical and biotechnology companiesbusiness administration of research and development organizations; holding company services performed for third partiesbusiness managementbusiness administrationproviding office functions; holding company services performed for third partiesnamely developing marketing strategyprofessional business and organisational consultancy and management of the business interests of others and legally independent companies; business management and organization consultancy; advisory services for business management; business administration; providing office functions; planning and monitoring of business developments with regard to organisational matters in the nature of business organisational consultation
Classe 42
Science and technology servicesresearch in the field of cancer; medical research laboratory services; development of pharmaceutical preparations and medicines; clinical research in the field of cancer diagnosis and treatment for medical and scientific purposes; research relating to biotechnology; scientific research consultancy services; biological analysisbiochemical analysischemical analysisscientific analysisall being scientific research; scientific research in the field of genetics and genetic engineering
Classe 44
Medical services; medical diagnostic services; medical in-vitro diagnostic services for medical and pharmaceutical purposes; medical services in the fields of pathologygenetic sciencehuman geneticsmolecular pathologiesmolecular biologymicrobiologybiotechnology and laboratory medicine; medical diagnostic services using histologycytologyimmunohistologyimmunohistochemistryin situ hybridisationpolymerase chain reaction (PCR)next generation sequencing (NGS)microarray hybridisation in the nature of genetic chip or biochip hybridisationflow cytometry and isolation of biomolecules including DNARNA and proteins; medical counseling; pharmaceutical services in the nature of pharmaceutical advice in the field of diagnosing and treating cancer; pharmaceutical advice; medical and health clinic services relating to DNAgenetics and genetic testing; medical pathology services; genetic testing for medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
47 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/07/2026
FIMP
FINAL DISPOSITION PROCESSED
06/07/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30/03/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
30/12/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
30/12/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/11/2025
PUBO
PUBLISHED FOR OPPOSITION
11/11/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/11/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/11/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/10/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
08/10/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/10/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
08/10/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/09/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/09/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/09/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
15/09/2025
GNRT
NON-FINAL ACTION E-MAILED
15/09/2025
CNRT
NON-FINAL ACTION WRITTEN
15/09/2025
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
10/09/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
29/08/2025
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
26/08/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/08/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
13/08/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
31/07/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
31/07/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
31/07/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
31/07/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
31/07/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/03/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/03/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/03/2025
RFNT
REFUSAL PROCESSED BY IB
09/02/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
22/01/2025
RFRR
REFUSAL PROCESSED BY MPU
22/01/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
27/12/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/06/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/06/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/06/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/06/2024
CNRT
NON-FINAL ACTION WRITTEN
31/05/2024
DOCK
ASSIGNED TO EXAMINER
30/05/2024
MAFR
APPLICATION FILING RECEIPT MAILED
24/04/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/03/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
14/03/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ZYTOMICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.